New Enterprise Associates

Abcuro develops immunotherapies targeting autoimmunity and cancer. Founded in 2015, the company uses bioinformatics and ex-vivo validation to uncover novel immune system targets.

Cardurion Pharmaceuticals, LLC, established in 2017 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for heart failure and other cardiovascular diseases. The company is advancing clinical programs that target PDE9 and CaMKII inhibition, utilizing its expertise in cardiovascular signaling pathways to address significant unmet patient needs.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

X4 Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel oral small molecule therapeutics targeting chemokine receptor CXCR4. Its lead drug candidate, mavorixafor (X4P-001), is in Phase III trials for the treatment of WHIM syndrome and has shown promising results in other indications such as severe congenital neutropenia and clear cell renal cell carcinoma.

Founded in 2018, NODAR specializes in developing camera-based 3D vision systems for autonomous vehicles. Its flagship product, Hammerhead, uses off-the-shelf cameras to deliver long-range, depth-sensing capabilities, enhancing safety features like forward collision warning and automatic emergency braking.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, established in 2011. The company specializes in the development and commercialization of Haduvio, an oral extended-release formulation of nalbuphine. Haduvio is currently undergoing a Phase IIb/III clinical trial, known as the PRISM trial, aimed at treating chronic pruritus associated with prurigo nodularis. Additionally, Trevi is exploring the use of nalbuphine ER for other serious neurologically mediated conditions, including chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in individuals with Parkinson’s disease. The treatment targets conditions that share a common pathophysiology mediated through opioid receptors in the central and peripheral nervous systems.

Proof of Learn is a Boston-based company founded in 2021 that serves as a talent marketplace for emerging developers by focusing on education, upskilling, and job placement. It operates Metacrafters.io, a multichain learn-to-earn platform designed to teach users how to write smart contracts and build on-chain applications. By leveraging blockchain technology, Proof of Learn aims to provide equal access to education and next-generation job opportunities globally. Its innovative approach enables learners to acquire skills, earn rewards, and secure employment in the evolving Web3 landscape.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

Tulip Interfaces is a technology company that creates shop‑floor applications for the manufacturing sector. Its no‑code platform integrates sensor data, digital work instructions, real‑time visualization, and operator inputs to connect existing equipment and streamline operations. The solution is used by firms in consumer electronics, pharmaceuticals, apparel, medical devices, aerospace, defense, automotive, and contract manufacturing to improve productivity, quality, and operational visibility. Founded in 2012, the company is headquartered in Somerville, Massachusetts.

Berkshire Grey, Inc. is a technology company specializing in the development of artificial intelligence-driven robotic and automated material handling systems. Founded in 2013 and based in Lexington, Massachusetts, the company focuses on automating tasks traditionally performed by humans in commercial settings, enhancing efficiency in fulfillment, supply chain, and logistics operations. Its offerings include a range of robotic solutions, such as autonomous picking and sorting systems, mobile robotic units, and dynamic parcel sortation technologies. Additionally, Berkshire Grey provides electromechanical solutions that incorporate vision systems and advanced scanning technologies. By leveraging AI, computer vision, and machine learning, the company's systems enable clients to achieve higher accuracy and throughput speeds while managing diverse product assortments. The majority of its revenue is generated from North America, positioning Berkshire Grey as a significant player in the automation landscape.

Affinia Therapeutics develops adeno-associated virus (AAV) gene therapies for muscular and central nervous system diseases. The company uses an AAV vector design platform built on synthetic and systems biology, high-throughput screening, and tissue- and single-cell-resolution analyses to create vectors with improved properties. It leverages sequencing, artificial intelligence, and structural modeling to enable rational design of therapies. Headquartered in Waltham, Massachusetts, Affinia Therapeutics was founded in 2019 and targets diseases with significant unmet needs in muscle and CNS.

Burrow, Inc. is a New York-based company that designs, manufactures, and supplies luxury furniture for residential use. Founded in 2016, Burrow specializes in creating easy-to-move and customizable seating options such as sofas, sectionals, loveseats, and armchairs, as well as tables, rugs, and various accessories. The furniture is crafted from sustainably-sourced hardwood and features non-toxic, scratch- and stain-resistant fabrics. Burrow aims to provide customers with comfortable and stylish furnishing alternatives while avoiding traditional retail markups. The company operates showrooms in several states, including Washington, Massachusetts, Texas, and California, and also sells its products online. Additionally, Burrow has a manufacturing facility located in Mexico City, Mexico.

DataRobot develops an automated machine learning platform that enables users across various industries to build predictive models. Its cloud-based solution, DataRobot Cloud, offers a project-based curriculum for gaining insights from data scientists. The company also provides DataRobot MLOps for deploying and managing machine learning models, along with enterprise features like flexible deployment and governance in its DataRobot Enterprise solution.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

Affinia Therapeutics develops adeno-associated virus (AAV) gene therapies for muscular and central nervous system diseases. The company uses an AAV vector design platform built on synthetic and systems biology, high-throughput screening, and tissue- and single-cell-resolution analyses to create vectors with improved properties. It leverages sequencing, artificial intelligence, and structural modeling to enable rational design of therapies. Headquartered in Waltham, Massachusetts, Affinia Therapeutics was founded in 2019 and targets diseases with significant unmet needs in muscle and CNS.

Akouos is a biotechnology company focused on precision genetic medicine to restore and preserve hearing. Based in Boston, it develops gene therapies using a proprietary adeno-associated viral vector platform and delivery approaches to treat sensorineural hearing loss in genetically defined populations. The company's lead program, AK-OTOF, targets hearing loss caused by mutations in the OTOF gene. Akouos pursues research and development across gene-based interventions aimed at improving auditory function and long-term sensory outcomes. It has collaborations with academic and industry partners, including Massachusetts Eye and Ear and Lonza, to advance discovery and manufacturing capabilities. Founded in 2016, Akouos addresses unmet clinical needs in auditory health by seeking to restore physiologic hearing through targeted genetic therapies.

Berkshire Grey, Inc. is a technology company specializing in the development of artificial intelligence-driven robotic and automated material handling systems. Founded in 2013 and based in Lexington, Massachusetts, the company focuses on automating tasks traditionally performed by humans in commercial settings, enhancing efficiency in fulfillment, supply chain, and logistics operations. Its offerings include a range of robotic solutions, such as autonomous picking and sorting systems, mobile robotic units, and dynamic parcel sortation technologies. Additionally, Berkshire Grey provides electromechanical solutions that incorporate vision systems and advanced scanning technologies. By leveraging AI, computer vision, and machine learning, the company's systems enable clients to achieve higher accuracy and throughput speeds while managing diverse product assortments. The majority of its revenue is generated from North America, positioning Berkshire Grey as a significant player in the automation landscape.

Black Diamond Therapeutics discovers and develops small molecule therapies for precision oncology. It focuses on allosteric mutations in kinases related to cancer, with a lead product candidate targeting non-canonical ErbB kinase mutations.

Upskill designs and develops augmented reality software for industrial workforces. Its flagship platform, Skylight, enables companies to create smart glasses applications for various business scenarios, transforming operations using wearable devices. Serving industries such as manufacturing, healthcare, retail, and logistics, Upskill improves productivity, reduces errors, and enhances training.

DataRobot develops an automated machine learning platform that enables users across various industries to build predictive models. Its cloud-based solution, DataRobot Cloud, offers a project-based curriculum for gaining insights from data scientists. The company also provides DataRobot MLOps for deploying and managing machine learning models, along with enterprise features like flexible deployment and governance in its DataRobot Enterprise solution.

Burrow, Inc. is a New York-based company that designs, manufactures, and supplies luxury furniture for residential use. Founded in 2016, Burrow specializes in creating easy-to-move and customizable seating options such as sofas, sectionals, loveseats, and armchairs, as well as tables, rugs, and various accessories. The furniture is crafted from sustainably-sourced hardwood and features non-toxic, scratch- and stain-resistant fabrics. Burrow aims to provide customers with comfortable and stylish furnishing alternatives while avoiding traditional retail markups. The company operates showrooms in several states, including Washington, Massachusetts, Texas, and California, and also sells its products online. Additionally, Burrow has a manufacturing facility located in Mexico City, Mexico.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, that specializes in developing and commercializing therapeutics for patients with rare genetic disorders of hemoglobin. Founded in 2016, the company is advancing IMR-687, an oral, once-daily therapeutic designed to treat sickle cell disease and beta-thalassemia. IMR-687 is a highly selective small molecule inhibitor of PDE9, engineered to have a multimodal mechanism of action that impacts various cell types, including red blood cells and white blood cells, as well as adhesion mediators. Through its innovative approach, Imara aims to provide disease-modifying treatments for individuals affected by hemoglobinopathies.

Tulip Interfaces is a technology company that creates shop‑floor applications for the manufacturing sector. Its no‑code platform integrates sensor data, digital work instructions, real‑time visualization, and operator inputs to connect existing equipment and streamline operations. The solution is used by firms in consumer electronics, pharmaceuticals, apparel, medical devices, aerospace, defense, automotive, and contract manufacturing to improve productivity, quality, and operational visibility. Founded in 2012, the company is headquartered in Somerville, Massachusetts.

Black Diamond Therapeutics discovers and develops small molecule therapies for precision oncology. It focuses on allosteric mutations in kinases related to cancer, with a lead product candidate targeting non-canonical ErbB kinase mutations.

Tiburio Therapeutics, founded in 2018 and based in Cambridge, Massachusetts, specializes in developing and manufacturing medicines for rare endocrine diseases and tumors related to the endocrine system. The company's primary focus is on TBR-760, a drug candidate designed to treat non-functioning pituitary adenoma (NFPA) using a dopamine-somatostatin chimeric molecule aimed at shrinking or halting tumor growth. Additionally, Tiburio explores other compounds like TBR-065 for treating rare endocrine diseases where effective treatments are limited.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, established in 2011. The company specializes in the development and commercialization of Haduvio, an oral extended-release formulation of nalbuphine. Haduvio is currently undergoing a Phase IIb/III clinical trial, known as the PRISM trial, aimed at treating chronic pruritus associated with prurigo nodularis. Additionally, Trevi is exploring the use of nalbuphine ER for other serious neurologically mediated conditions, including chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in individuals with Parkinson’s disease. The treatment targets conditions that share a common pathophysiology mediated through opioid receptors in the central and peripheral nervous systems.

DataRobot develops an automated machine learning platform that enables users across various industries to build predictive models. Its cloud-based solution, DataRobot Cloud, offers a project-based curriculum for gaining insights from data scientists. The company also provides DataRobot MLOps for deploying and managing machine learning models, along with enterprise features like flexible deployment and governance in its DataRobot Enterprise solution.

Formlabs designs and manufactures professional 3D printing systems and materials for engineers, designers, educators, and manufacturers. The company offers high-resolution stereolithography printers such as Form 3, Form 3B, and Form 3L, along with post-processing equipment Form Wash and Form Cure, and the SLS-based Fuse 1 printer. It develops in-house high-performance resins and materials used across industries including education, dentistry, healthcare, jewelry, and manufacturing. Its software ecosystem includes PreForm, which prepares models for printing, and Form Cell for automated manufacturing. Formlabs serves customers worldwide and maintains headquarters in Somerville, Massachusetts with international offices. The company focuses on enabling designers and engineers to produce detailed, functional parts and complex geometries, expanding access to professional-grade 3D printing through scalable hardware, materials, and software solutions.

Akouos is a biotechnology company focused on precision genetic medicine to restore and preserve hearing. Based in Boston, it develops gene therapies using a proprietary adeno-associated viral vector platform and delivery approaches to treat sensorineural hearing loss in genetically defined populations. The company's lead program, AK-OTOF, targets hearing loss caused by mutations in the OTOF gene. Akouos pursues research and development across gene-based interventions aimed at improving auditory function and long-term sensory outcomes. It has collaborations with academic and industry partners, including Massachusetts Eye and Ear and Lonza, to advance discovery and manufacturing capabilities. Founded in 2016, Akouos addresses unmet clinical needs in auditory health by seeking to restore physiologic hearing through targeted genetic therapies.

Tamr is an enterprise data unification company based in Cambridge, Massachusetts. It builds a platform that uses machine learning and human insight to connect and enrich disparate data sources at scale. The solution supports data preparation, mastering, and integration for industries such as financial services, life sciences, government, oil and gas, manufacturing, consumer packaged goods, telecommunications, and media. It offers applications for procurement analytics, clinical data conversion, media analytics, and customer data integration. The platform helps organizations derive actionable insights and improve decision-making. Founded in 2013 by database experts, it has deployed in production at information services providers, pharmaceutical firms, and retailers.

Automation Anywhere, Inc. is a global leader in Robotic Process Automation (RPA), specializing in the development of AI-powered software solutions designed to enhance business efficiency. Founded in 2003 and headquartered in San Jose, California, the company offers a cloud-native platform that integrates RPA with artificial intelligence, machine learning, and analytics. Its flagship products include Automation Anywhere Enterprise, which automates IT and business processes; Automation Anywhere Server for streamlined business operations; and IQ Bot, a cognitive automation solution that addresses complex business tasks. Additionally, the company provides a comprehensive suite of testing tools, such as Testing Anywhere, which supports quality assurance across various platforms. Automation Anywhere also offers consulting services and collaborates strategically with Microsoft Azure. The company has expanded its presence internationally with offices in several major cities across the United States, Europe, the Middle East, and Asia.

Catalog Technologies Inc. specializes in a DNA-based platform that revolutionizes digital data storage and computation. Founded in 2016 and headquartered in Boston, Massachusetts, the company provides a method for encoding digital information into DNA, making it a viable and cost-effective solution for long-term data archiving. By leveraging advanced synthetic biology technologies, Catalog aims to transform how information is stored, allowing customers to utilize DNA molecules as a primary medium for digital records. This innovative approach positions Catalog at the forefront of next-generation data storage solutions.

Burrow, Inc. is a New York-based company that designs, manufactures, and supplies luxury furniture for residential use. Founded in 2016, Burrow specializes in creating easy-to-move and customizable seating options such as sofas, sectionals, loveseats, and armchairs, as well as tables, rugs, and various accessories. The furniture is crafted from sustainably-sourced hardwood and features non-toxic, scratch- and stain-resistant fabrics. Burrow aims to provide customers with comfortable and stylish furnishing alternatives while avoiding traditional retail markups. The company operates showrooms in several states, including Washington, Massachusetts, Texas, and California, and also sells its products online. Additionally, Burrow has a manufacturing facility located in Mexico City, Mexico.

Upskill designs and develops augmented reality software for industrial workforces. Its flagship platform, Skylight, enables companies to create smart glasses applications for various business scenarios, transforming operations using wearable devices. Serving industries such as manufacturing, healthcare, retail, and logistics, Upskill improves productivity, reduces errors, and enhances training.

Centrexion Therapeutics is a late-stage biopharmaceutical company dedicated to developing non-opioid, non-addictive therapies for chronic pain management. Its pipeline includes CNTX-4975 in Phase III trials for knee osteoarthritis pain, and other candidates in various stages of clinical development targeting diverse pain conditions.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

Akouos is a biotechnology company focused on precision genetic medicine to restore and preserve hearing. Based in Boston, it develops gene therapies using a proprietary adeno-associated viral vector platform and delivery approaches to treat sensorineural hearing loss in genetically defined populations. The company's lead program, AK-OTOF, targets hearing loss caused by mutations in the OTOF gene. Akouos pursues research and development across gene-based interventions aimed at improving auditory function and long-term sensory outcomes. It has collaborations with academic and industry partners, including Massachusetts Eye and Ear and Lonza, to advance discovery and manufacturing capabilities. Founded in 2016, Akouos addresses unmet clinical needs in auditory health by seeking to restore physiologic hearing through targeted genetic therapies.

DataRobot develops an automated machine learning platform that enables users across various industries to build predictive models. Its cloud-based solution, DataRobot Cloud, offers a project-based curriculum for gaining insights from data scientists. The company also provides DataRobot MLOps for deploying and managing machine learning models, along with enterprise features like flexible deployment and governance in its DataRobot Enterprise solution.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, established in 2011. The company specializes in the development and commercialization of Haduvio, an oral extended-release formulation of nalbuphine. Haduvio is currently undergoing a Phase IIb/III clinical trial, known as the PRISM trial, aimed at treating chronic pruritus associated with prurigo nodularis. Additionally, Trevi is exploring the use of nalbuphine ER for other serious neurologically mediated conditions, including chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in individuals with Parkinson’s disease. The treatment targets conditions that share a common pathophysiology mediated through opioid receptors in the central and peripheral nervous systems.

Desktop Metal is a global developer and manufacturer of additive manufacturing technologies, materials, and software for industrial production. The company offers a range of metal 3D printing systems, including the Production System for high-volume manufacturing, the Shop System for machine shops, the Studio System for office environments, and the Fiber printer for desktop use. It supplies materials and software that support metal, polymer, sand, and ceramic applications, enabling on-demand, digital mass production with improved speed, cost efficiency, and part quality. Desktop Metal serves automotive, aerospace, healthcare, consumer products, heavy industry, machine design, and research and development customers and operates worldwide from headquarters in Burlington, Massachusetts.

Catalog Technologies Inc. specializes in a DNA-based platform that revolutionizes digital data storage and computation. Founded in 2016 and headquartered in Boston, Massachusetts, the company provides a method for encoding digital information into DNA, making it a viable and cost-effective solution for long-term data archiving. By leveraging advanced synthetic biology technologies, Catalog aims to transform how information is stored, allowing customers to utilize DNA molecules as a primary medium for digital records. This innovative approach positions Catalog at the forefront of next-generation data storage solutions.

Tulip Interfaces is a technology company that creates shop‑floor applications for the manufacturing sector. Its no‑code platform integrates sensor data, digital work instructions, real‑time visualization, and operator inputs to connect existing equipment and streamline operations. The solution is used by firms in consumer electronics, pharmaceuticals, apparel, medical devices, aerospace, defense, automotive, and contract manufacturing to improve productivity, quality, and operational visibility. Founded in 2012, the company is headquartered in Somerville, Massachusetts.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

Upskill designs and develops augmented reality software for industrial workforces. Its flagship platform, Skylight, enables companies to create smart glasses applications for various business scenarios, transforming operations using wearable devices. Serving industries such as manufacturing, healthcare, retail, and logistics, Upskill improves productivity, reduces errors, and enhances training.

Desktop Metal is a global developer and manufacturer of additive manufacturing technologies, materials, and software for industrial production. The company offers a range of metal 3D printing systems, including the Production System for high-volume manufacturing, the Shop System for machine shops, the Studio System for office environments, and the Fiber printer for desktop use. It supplies materials and software that support metal, polymer, sand, and ceramic applications, enabling on-demand, digital mass production with improved speed, cost efficiency, and part quality. Desktop Metal serves automotive, aerospace, healthcare, consumer products, heavy industry, machine design, and research and development customers and operates worldwide from headquarters in Burlington, Massachusetts.

ClearMotion, Inc. is an automotive technology company that specializes in developing advanced suspension systems to enhance vehicle comfort and handling. Founded out of MIT in 2008 and based in Billerica, Massachusetts, with operations in Nuneaton, United Kingdom, ClearMotion integrates hardware and software to create a proactive ride system that anticipates and counteracts shocks and vibrations from uneven road surfaces. This innovative technology not only improves ride quality but also enhances the overall user experience in vehicles. By mapping road surfaces in real-time, ClearMotion's system can mitigate the effects of road roughness almost instantaneously, ensuring a smoother ride for both drivers and passengers.

Guideline is a retirement plan technology company that automates the administration and compliance of employer-sponsored 401(k) plans. It provides an online platform that covers plan design and setup, enrollment and education, administration and recordkeeping, compliance and reporting, and investment management, integrating participants' financial information to offer ongoing recommendations. The platform handles payroll integration and streamlined workflow for small and growing businesses, with transparent pricing based on a flat fee per participant rather than asset-based charges. Founded in 2015, Guideline is headquartered in San Mateo, California, with an additional office in Portland, Maine.

Docent Health is a company based in Cambridge, Massachusetts, that specializes in developing software and mobile applications aimed at enhancing patient care and engagement for health systems. Its enterprise consumer engagement platform integrates digital and human interactions to provide personalized support for patients, guiding them according to their specific needs and preferences. By utilizing intelligent, real-time text messaging, Docent Health focuses on fostering lasting patient relationships and improving customer experiences. The company's approach combines insights from various industries, including retail and hospitality, to deliver customer-centric care that enhances patient satisfaction, increases customer lifetime value, and helps health systems grow their market share.

Mersana Therapeutics is a clinical-stage biopharmaceutical company that develops antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. It leverages proprietary ADC platforms, including Dolaflexin, Dolasynthen, and Immunosynthen, to create a diverse pipeline of product candidates designed to improve therapeutic benefit and address oncology indications underserved by traditional ADCs. The lead candidate XMT-1536 targets NaPi2b and is in Phase I trials for ovarian cancer, non-small cell lung cancer, and other indications. The company also advances additional programs such as Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175, reflecting its focus on next-generation ADCs. Mersana is headquartered in Cambridge, Massachusetts, and was founded in 2005.

Spine Wave, Inc. is a medical device company that specializes in the development and marketing of innovative solutions for spinal disorders. Founded in 2001 and based in Shelton, Connecticut, the company offers a diverse range of products including expandable PEEK spacers, interbody devices for posterior surgery, and lateral stabilization systems. Its offerings also encompass the GraftMag Graft Delivery System for large bone graft delivery, fixation products for treating thoracolumbar spine conditions, and anterior cervical plate systems for spinal fusion. Spine Wave prioritizes a surgeon-driven product development approach, enabling it to create a differentiated portfolio of less invasive and efficient surgical solutions aimed at restoring spinal function and improving patients' quality of life. The company's products are distributed through various channels, ensuring wide accessibility for spine surgeons and their patients.

AVEO Oncology is a biopharmaceutical company that specializes in developing and commercializing targeted therapies for oncology and other unmet medical needs. The company is known for its lead product, FOTIVDA (tivozanib), an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used in the treatment of renal cell carcinoma (RCC). AVEO has completed a Phase III trial for tivozanib and is exploring its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, the company is developing other therapeutic candidates, including Ficlatuzumab, an antibody for various cancers, and AV-203, a monoclonal antibody for esophageal cancer, which has completed Phase I trials. AVEO's preclinical pipeline includes promising products aimed at treating conditions such as cachexia and pulmonary arterial hypertension. Headquartered in Boston, Massachusetts, the company was founded in 2001 and has established collaborations with various pharmaceutical firms to enhance its development efforts.

Desktop Metal is a global developer and manufacturer of additive manufacturing technologies, materials, and software for industrial production. The company offers a range of metal 3D printing systems, including the Production System for high-volume manufacturing, the Shop System for machine shops, the Studio System for office environments, and the Fiber printer for desktop use. It supplies materials and software that support metal, polymer, sand, and ceramic applications, enabling on-demand, digital mass production with improved speed, cost efficiency, and part quality. Desktop Metal serves automotive, aerospace, healthcare, consumer products, heavy industry, machine design, and research and development customers and operates worldwide from headquarters in Burlington, Massachusetts.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, that specializes in developing and commercializing therapeutics for patients with rare genetic disorders of hemoglobin. Founded in 2016, the company is advancing IMR-687, an oral, once-daily therapeutic designed to treat sickle cell disease and beta-thalassemia. IMR-687 is a highly selective small molecule inhibitor of PDE9, engineered to have a multimodal mechanism of action that impacts various cell types, including red blood cells and white blood cells, as well as adhesion mediators. Through its innovative approach, Imara aims to provide disease-modifying treatments for individuals affected by hemoglobinopathies.

Tesaro, Inc. is an oncology-focused biopharmaceutical company established in 2010 and headquartered in Waltham, Massachusetts. The company is dedicated to developing and commercializing cancer therapeutics and supportive care products. Its primary offerings include ZEJULA, a potent oral poly polymerase inhibitor for the maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer, and VARUBI, a neurokinin-1 receptor antagonist designed to prevent chemotherapy-induced nausea and vomiting. Additionally, Tesaro is engaged in the development of several immunotherapy antibody candidates, including TSR-042, TSR-022, and TSR-033, all currently in phase I clinical trials. The company collaborates with various organizations, such as AnaptysBio, Janssen Biotech, and Merck Sharp & Dohme, to enhance its research and development efforts. Tesaro aims to leverage its management team's expertise to identify and commercialize innovative treatments that improve the lives of cancer patients. As of January 2019, Tesaro operates as a subsidiary of GlaxoSmithKline.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

DataRobot develops an automated machine learning platform that enables users across various industries to build predictive models. Its cloud-based solution, DataRobot Cloud, offers a project-based curriculum for gaining insights from data scientists. The company also provides DataRobot MLOps for deploying and managing machine learning models, along with enterprise features like flexible deployment and governance in its DataRobot Enterprise solution.

Docent Health is a company based in Cambridge, Massachusetts, that specializes in developing software and mobile applications aimed at enhancing patient care and engagement for health systems. Its enterprise consumer engagement platform integrates digital and human interactions to provide personalized support for patients, guiding them according to their specific needs and preferences. By utilizing intelligent, real-time text messaging, Docent Health focuses on fostering lasting patient relationships and improving customer experiences. The company's approach combines insights from various industries, including retail and hospitality, to deliver customer-centric care that enhances patient satisfaction, increases customer lifetime value, and helps health systems grow their market share.

DOTS Technology Corp, founded in 2013 and located in Natick, Massachusetts, operates a diagnostic platform designed to assist consumers with food allergies. The company is focused on developing a food allergen detection system that allows users to test food on the spot, providing immediate information to enhance decision-making and improve the overall quality of life for individuals affected by food allergies. By advancing point-of-care detection technology, DOTS aims to address the needs of millions of consumers and has applications in both consumer and industrial sectors.

AVEO Oncology is a biopharmaceutical company that specializes in developing and commercializing targeted therapies for oncology and other unmet medical needs. The company is known for its lead product, FOTIVDA (tivozanib), an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used in the treatment of renal cell carcinoma (RCC). AVEO has completed a Phase III trial for tivozanib and is exploring its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, the company is developing other therapeutic candidates, including Ficlatuzumab, an antibody for various cancers, and AV-203, a monoclonal antibody for esophageal cancer, which has completed Phase I trials. AVEO's preclinical pipeline includes promising products aimed at treating conditions such as cachexia and pulmonary arterial hypertension. Headquartered in Boston, Massachusetts, the company was founded in 2001 and has established collaborations with various pharmaceutical firms to enhance its development efforts.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, that specializes in developing and commercializing therapeutics for patients with rare genetic disorders of hemoglobin. Founded in 2016, the company is advancing IMR-687, an oral, once-daily therapeutic designed to treat sickle cell disease and beta-thalassemia. IMR-687 is a highly selective small molecule inhibitor of PDE9, engineered to have a multimodal mechanism of action that impacts various cell types, including red blood cells and white blood cells, as well as adhesion mediators. Through its innovative approach, Imara aims to provide disease-modifying treatments for individuals affected by hemoglobinopathies.

Sundar, Inc. operates a curated digital platform aimed at enhancing material discovery and supplier sourcing within the apparel and design industries. Founded in 2013 and based in Boston, Massachusetts, the company connects creative professionals with quality materials and qualified vendors on a global scale. By providing centralized digital catalogs, sophisticated search capabilities, and data-driven insights, Sundar streamlines the sourcing process for both emerging and established designers, facilitating collaboration with manufacturers, suppliers, and artisans. The platform is designed to address the inefficiencies of the traditional supply chain in the trillion-dollar apparel industry, enabling users to discover and source textiles and raw materials more effectively. Sundar's innovative approach has garnered recognition from industry leaders and has been featured in prominent publications, reflecting its impact on modern design and production practices.

Upskill designs and develops augmented reality software for industrial workforces. Its flagship platform, Skylight, enables companies to create smart glasses applications for various business scenarios, transforming operations using wearable devices. Serving industries such as manufacturing, healthcare, retail, and logistics, Upskill improves productivity, reduces errors, and enhances training.

Desktop Metal is a global developer and manufacturer of additive manufacturing technologies, materials, and software for industrial production. The company offers a range of metal 3D printing systems, including the Production System for high-volume manufacturing, the Shop System for machine shops, the Studio System for office environments, and the Fiber printer for desktop use. It supplies materials and software that support metal, polymer, sand, and ceramic applications, enabling on-demand, digital mass production with improved speed, cost efficiency, and part quality. Desktop Metal serves automotive, aerospace, healthcare, consumer products, heavy industry, machine design, and research and development customers and operates worldwide from headquarters in Burlington, Massachusetts.

Founded in 2013, GLAMSQUAD is a New York-based company specializing in on-demand beauty services. It offers hair styling and makeup services through trained professionals who visit clients at their homes, offices, or events across major U.S. cities. The company also retails its own line of hair care products.

Acquia provides a cloud-based platform enabling businesses worldwide to build, deliver, and optimize digital experiences. With clients such as BBC, Nasdaq, Stanford University, and the Australian Government, Acquia accelerates time-to-market and enhances customer engagement through cross-channel, contextually relevant digital experiences.

Guideline is a retirement plan technology company that automates the administration and compliance of employer-sponsored 401(k) plans. It provides an online platform that covers plan design and setup, enrollment and education, administration and recordkeeping, compliance and reporting, and investment management, integrating participants' financial information to offer ongoing recommendations. The platform handles payroll integration and streamlined workflow for small and growing businesses, with transparent pricing based on a flat fee per participant rather than asset-based charges. Founded in 2015, Guideline is headquartered in San Mateo, California, with an additional office in Portland, Maine.

Rhythm Metabolic is the subsidiary of Rhythm Pharmaceuticals that develops setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway. It was established in 2013 and is headquartered in Boston, Massachusetts.

Ra Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapeutics for diseases linked to the excessive activation of the complement system. Utilizing a peptide chemistry platform, the company produces synthetic macrocyclic peptides that offer the specificity and diversity of antibodies alongside the pharmacological advantages of small molecules. Its lead product candidate, Zilucoplan, is an injectable treatment that has completed Phase II clinical trials for generalized myasthenia gravis and paroxysmal nocturnal hemoglobinuria, as well as a Phase Ib trial for patients with renal impairment. In addition to Zilucoplan, Ra Pharmaceuticals is advancing pre-clinical programs targeting Factor D inhibition for C3 glomerulonephritis and dense deposit disease, among other conditions. The company has also established a collaboration with Merck & Co., Inc. to explore orally available cyclic peptides for cardiovascular targets. Founded in 2008, Ra Pharmaceuticals operates as a subsidiary of UCB SA.

Tamr is an enterprise data unification company based in Cambridge, Massachusetts. It builds a platform that uses machine learning and human insight to connect and enrich disparate data sources at scale. The solution supports data preparation, mastering, and integration for industries such as financial services, life sciences, government, oil and gas, manufacturing, consumer packaged goods, telecommunications, and media. It offers applications for procurement analytics, clinical data conversion, media analytics, and customer data integration. The platform helps organizations derive actionable insights and improve decision-making. Founded in 2013 by database experts, it has deployed in production at information services providers, pharmaceutical firms, and retailers.

XTuit Pharmaceuticals, Inc., established in 2011 and headquartered in Waltham, Massachusetts, is a biopharmaceutical company dedicated to developing innovative therapeutics targeting the disease-promoting microenvironment in fibrotic diseases and cancer. The company focuses on creating pharmaceutical preparations for diagnosing and treating oncological, tumor, and inflammatory diseases by pursuing novel approaches that target the tumor microenvironment. Its drug development pipeline and clinical biomarker platform aim to create drugs that inhibit extracellular matrix synthesis and stabilization, and silence activated stromal cells through pleiotropic mechanisms.

Mersana Therapeutics is a clinical-stage biopharmaceutical company that develops antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. It leverages proprietary ADC platforms, including Dolaflexin, Dolasynthen, and Immunosynthen, to create a diverse pipeline of product candidates designed to improve therapeutic benefit and address oncology indications underserved by traditional ADCs. The lead candidate XMT-1536 targets NaPi2b and is in Phase I trials for ovarian cancer, non-small cell lung cancer, and other indications. The company also advances additional programs such as Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175, reflecting its focus on next-generation ADCs. Mersana is headquartered in Cambridge, Massachusetts, and was founded in 2005.

GuideSpark, Inc. is a company that specializes in developing employee communication software aimed at enhancing engagement and interaction within organizations. Its primary offering, the GuideSpark Communicate Cloud, allows human resource teams to implement communication campaigns and create multi-format content experiences that facilitate the adoption of various HR programs, including benefits, performance management, and compensation. The platform also features Total Rewards communication journeys, which help employees appreciate their company's investment in total rewards, alongside tools for talent management and promoting company culture and core values. Founded in 2008 and headquartered in Redwood City, California, GuideSpark serves over 1,000 enterprise customers, guiding them through organizational change by fostering employee engagement and behavior modification to achieve critical business goals. The company also has additional offices in Portland, Boston, San Francisco, and New York.

Surface Oncology, Inc. is a clinical-stage immuno-oncology company based in Cambridge, Massachusetts, focused on developing innovative cancer therapies. The company specializes in creating human immunoglobulin isotype G4 monoclonal antibodies, including SRF231, which inhibits CD47; NZV930, which targets CD73; SRF617, which inhibits CD39; SRF388, aimed at interleukin 27; and SRF813, which targets CD112R. Additionally, Surface Oncology is advancing several preclinical programs that address other critical elements of the tumor microenvironment, such as regulatory T cells and natural killer cells. The company has established strategic collaborations with Novartis Institutes for Biomedical Research and Merck Sharp & Dohme Corp. to advance the development of its therapies, including evaluating the combination of SRF617 with Merck’s KEYTRUDA. Founded in 2014, Surface Oncology aims to leverage novel immunotherapy targets and insights into cancer immuno-biology to enhance anti-tumor immune responses.

ClearMotion, Inc. is an automotive technology company that specializes in developing advanced suspension systems to enhance vehicle comfort and handling. Founded out of MIT in 2008 and based in Billerica, Massachusetts, with operations in Nuneaton, United Kingdom, ClearMotion integrates hardware and software to create a proactive ride system that anticipates and counteracts shocks and vibrations from uneven road surfaces. This innovative technology not only improves ride quality but also enhances the overall user experience in vehicles. By mapping road surfaces in real-time, ClearMotion's system can mitigate the effects of road roughness almost instantaneously, ensuring a smoother ride for both drivers and passengers.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

DataRobot develops an automated machine learning platform that enables users across various industries to build predictive models. Its cloud-based solution, DataRobot Cloud, offers a project-based curriculum for gaining insights from data scientists. The company also provides DataRobot MLOps for deploying and managing machine learning models, along with enterprise features like flexible deployment and governance in its DataRobot Enterprise solution.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

Solace Therapeutics, Inc. is a medical device company based in Framingham, Massachusetts, that specializes in developing non-surgical, office-based treatments for common bladder disorders, including stress urinary incontinence (SUI), overactive bladder (OAB), male voiding dysfunction, and lower urinary tract symptoms (LUTS). The company’s flagship product, the Vesair Bladder Control System, is a lightweight device designed to float within the urinary bladder, effectively addressing involuntary urinary leakage without the need for anesthesia or surgical intervention. Solace Therapeutics aims to enhance patients' quality of life by offering a treatment option that minimizes the side effects often associated with traditional drug and surgical therapies, allowing for a reversible and less intrusive approach to bladder health.

Acquia provides a cloud-based platform enabling businesses worldwide to build, deliver, and optimize digital experiences. With clients such as BBC, Nasdaq, Stanford University, and the Australian Government, Acquia accelerates time-to-market and enhances customer engagement through cross-channel, contextually relevant digital experiences.

Upskill designs and develops augmented reality software for industrial workforces. Its flagship platform, Skylight, enables companies to create smart glasses applications for various business scenarios, transforming operations using wearable devices. Serving industries such as manufacturing, healthcare, retail, and logistics, Upskill improves productivity, reduces errors, and enhances training.

Tamr is an enterprise data unification company based in Cambridge, Massachusetts. It builds a platform that uses machine learning and human insight to connect and enrich disparate data sources at scale. The solution supports data preparation, mastering, and integration for industries such as financial services, life sciences, government, oil and gas, manufacturing, consumer packaged goods, telecommunications, and media. It offers applications for procurement analytics, clinical data conversion, media analytics, and customer data integration. The platform helps organizations derive actionable insights and improve decision-making. Founded in 2013 by database experts, it has deployed in production at information services providers, pharmaceutical firms, and retailers.

Loxo Oncology, Inc. is a biopharmaceutical company based in Stamford, Connecticut, focused on developing and commercializing targeted therapies for genetically defined cancers in the United States. Founded in 2013, the company aims to bring innovative cancer treatments to the clinic by identifying actionable "driver mutations" in tumors. Its lead product candidate, larotrectinib, is an oral selective inhibitor of tropomyosin receptor kinase (TRK) and is undergoing various clinical trials for multiple cancer types, including lung, melanoma, and breast cancer. Loxo Oncology is also advancing several preclinical programs, including candidates targeting RET fusion proteins and FGFR isoforms. The company has established collaborations with several organizations to enhance its drug discovery efforts and optimize its clinical development strategies. As a subsidiary of Eli Lilly and Company, Loxo Oncology is dedicated to creating effective therapies that address specific genetic vulnerabilities in cancer patients.

Mersana Therapeutics is a clinical-stage biopharmaceutical company that develops antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. It leverages proprietary ADC platforms, including Dolaflexin, Dolasynthen, and Immunosynthen, to create a diverse pipeline of product candidates designed to improve therapeutic benefit and address oncology indications underserved by traditional ADCs. The lead candidate XMT-1536 targets NaPi2b and is in Phase I trials for ovarian cancer, non-small cell lung cancer, and other indications. The company also advances additional programs such as Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175, reflecting its focus on next-generation ADCs. Mersana is headquartered in Cambridge, Massachusetts, and was founded in 2005.

Kensho Technologies, Inc. is a provider of advanced analytics, artificial intelligence, machine learning, and data visualization systems tailored for global banks and investment institutions. The company develops Kensho Financial Analytics Software, which delivers scalable analytical solutions to enhance decision-making within commercial entities. Kensho's offerings also include the Kensho Applied Mind, a sophisticated AI software that enables natural language processing to address complex financial inquiries in plain English. Additionally, Kensho operates a national security division known as Koto. Founded in 2012 and headquartered in Cambridge, Massachusetts, Kensho has expanded its presence with offices in New York, McLean, and Pacific Palisades. As of April 2018, Kensho Technologies operates as a subsidiary of S&P Global Inc.

GuideSpark, Inc. is a company that specializes in developing employee communication software aimed at enhancing engagement and interaction within organizations. Its primary offering, the GuideSpark Communicate Cloud, allows human resource teams to implement communication campaigns and create multi-format content experiences that facilitate the adoption of various HR programs, including benefits, performance management, and compensation. The platform also features Total Rewards communication journeys, which help employees appreciate their company's investment in total rewards, alongside tools for talent management and promoting company culture and core values. Founded in 2008 and headquartered in Redwood City, California, GuideSpark serves over 1,000 enterprise customers, guiding them through organizational change by fostering employee engagement and behavior modification to achieve critical business goals. The company also has additional offices in Portland, Boston, San Francisco, and New York.

Philo is a streaming service that focuses on providing an entertainment-centric experience, offering a wide range of channels, networks, and shows for general media consumption. Inspired by Philo T. Farnsworth, the inventor of electronic television, the company began by targeting the college market and has since evolved into a comprehensive platform for next-generation TV viewing. Headquartered in San Francisco, with additional offices in New York and Cambridge, Massachusetts, Philo allows users to access live streaming of cable channels and major broadcasts. Its features include the ability to pause live channels, enabling viewers to enjoy prime-time television, live news, sports, and entertainment on various devices, including smartphones and computers.

Influitive Corporation, established in 2010 and headquartered in Toronto, Canada, with offices in Menlo Park, California, and Boston, Massachusetts, specializes in advocate marketing software solutions for B2B software and technology firms. Its flagship product, AdvocateHub, facilitates the creation of advocate communities, enabling customers, partners, and employees to engage in challenges such as referrals, reviews, and reference calls. This software integrates with Salesforce.com for activity tracking and is available via web portal or mobile app. Influitive also offers consulting services, providing coaching and training to help businesses implement and advance their advocate marketing strategies.

Influitive Corporation, established in 2010 and headquartered in Toronto, Canada, with offices in Menlo Park, California, and Boston, Massachusetts, specializes in advocate marketing software solutions for B2B software and technology firms. Its flagship product, AdvocateHub, facilitates the creation of advocate communities, enabling customers, partners, and employees to engage in challenges such as referrals, reviews, and reference calls. This software integrates with Salesforce.com for activity tracking and is available via web portal or mobile app. Influitive also offers consulting services, providing coaching and training to help businesses implement and advance their advocate marketing strategies.

Motus Therapeutics is a biotechnology company located in Boston, Massachusetts, focused on developing peptide therapeutics to address unmet needs in metabolic diseases. The company specializes in treatments for gastrointestinal disorders, with its lead product candidate, relamorelin, acting as a ghrelin agonist. Relamorelin is specifically designed for the treatment of diabetic gastroparesis, a gastrointestinal complication associated with diabetes, as well as other gastrointestinal functional disorders. Through its innovative approach, Motus Therapeutics aims to improve the quality of life for patients suffering from these conditions.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Influitive Corporation, established in 2010 and headquartered in Toronto, Canada, with offices in Menlo Park, California, and Boston, Massachusetts, specializes in advocate marketing software solutions for B2B software and technology firms. Its flagship product, AdvocateHub, facilitates the creation of advocate communities, enabling customers, partners, and employees to engage in challenges such as referrals, reviews, and reference calls. This software integrates with Salesforce.com for activity tracking and is available via web portal or mobile app. Influitive also offers consulting services, providing coaching and training to help businesses implement and advance their advocate marketing strategies.

Influitive Corporation, established in 2010 and headquartered in Toronto, Canada, with offices in Menlo Park, California, and Boston, Massachusetts, specializes in advocate marketing software solutions for B2B software and technology firms. Its flagship product, AdvocateHub, facilitates the creation of advocate communities, enabling customers, partners, and employees to engage in challenges such as referrals, reviews, and reference calls. This software integrates with Salesforce.com for activity tracking and is available via web portal or mobile app. Influitive also offers consulting services, providing coaching and training to help businesses implement and advance their advocate marketing strategies.

Mersana Therapeutics is a clinical-stage biopharmaceutical company that develops antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. It leverages proprietary ADC platforms, including Dolaflexin, Dolasynthen, and Immunosynthen, to create a diverse pipeline of product candidates designed to improve therapeutic benefit and address oncology indications underserved by traditional ADCs. The lead candidate XMT-1536 targets NaPi2b and is in Phase I trials for ovarian cancer, non-small cell lung cancer, and other indications. The company also advances additional programs such as Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175, reflecting its focus on next-generation ADCs. Mersana is headquartered in Cambridge, Massachusetts, and was founded in 2005.

Motus Therapeutics is a biotechnology company located in Boston, Massachusetts, focused on developing peptide therapeutics to address unmet needs in metabolic diseases. The company specializes in treatments for gastrointestinal disorders, with its lead product candidate, relamorelin, acting as a ghrelin agonist. Relamorelin is specifically designed for the treatment of diabetic gastroparesis, a gastrointestinal complication associated with diabetes, as well as other gastrointestinal functional disorders. Through its innovative approach, Motus Therapeutics aims to improve the quality of life for patients suffering from these conditions.

Solace Therapeutics, Inc. is a medical device company based in Framingham, Massachusetts, that specializes in developing non-surgical, office-based treatments for common bladder disorders, including stress urinary incontinence (SUI), overactive bladder (OAB), male voiding dysfunction, and lower urinary tract symptoms (LUTS). The company’s flagship product, the Vesair Bladder Control System, is a lightweight device designed to float within the urinary bladder, effectively addressing involuntary urinary leakage without the need for anesthesia or surgical intervention. Solace Therapeutics aims to enhance patients' quality of life by offering a treatment option that minimizes the side effects often associated with traditional drug and surgical therapies, allowing for a reversible and less intrusive approach to bladder health.

Philo is a streaming service that focuses on providing an entertainment-centric experience, offering a wide range of channels, networks, and shows for general media consumption. Inspired by Philo T. Farnsworth, the inventor of electronic television, the company began by targeting the college market and has since evolved into a comprehensive platform for next-generation TV viewing. Headquartered in San Francisco, with additional offices in New York and Cambridge, Massachusetts, Philo allows users to access live streaming of cable channels and major broadcasts. Its features include the ability to pause live channels, enabling viewers to enjoy prime-time television, live news, sports, and entertainment on various devices, including smartphones and computers.

SingleStore is a data technology company that provides a distributed SQL database platform designed for real-time transactions and analytics. Its offerings include SingleStore DB, a distributed SQL database that can run on bare metal, in the cloud, or in hybrid deployments for operational analytics, and SingleStore Managed Service, a cloud database-as-a-service that provides analytics across a cloud of choice. The platform combines transactional and analytical processing in a single engine, supports real-time querying, multi-model data, and scalable ingestion, and aims to modernize data platforms, secure workloads, and support customer analytics across industries such as financial services, media and communications, energy and utilities, government, retail, and technology. Headquartered in San Francisco with additional offices, the company serves global enterprises by enabling real-time insights from data.

Tesaro, Inc. is an oncology-focused biopharmaceutical company established in 2010 and headquartered in Waltham, Massachusetts. The company is dedicated to developing and commercializing cancer therapeutics and supportive care products. Its primary offerings include ZEJULA, a potent oral poly polymerase inhibitor for the maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer, and VARUBI, a neurokinin-1 receptor antagonist designed to prevent chemotherapy-induced nausea and vomiting. Additionally, Tesaro is engaged in the development of several immunotherapy antibody candidates, including TSR-042, TSR-022, and TSR-033, all currently in phase I clinical trials. The company collaborates with various organizations, such as AnaptysBio, Janssen Biotech, and Merck Sharp & Dohme, to enhance its research and development efforts. Tesaro aims to leverage its management team's expertise to identify and commercialize innovative treatments that improve the lives of cancer patients. As of January 2019, Tesaro operates as a subsidiary of GlaxoSmithKline.

Spine Wave, Inc. is a medical device company that specializes in the development and marketing of innovative solutions for spinal disorders. Founded in 2001 and based in Shelton, Connecticut, the company offers a diverse range of products including expandable PEEK spacers, interbody devices for posterior surgery, and lateral stabilization systems. Its offerings also encompass the GraftMag Graft Delivery System for large bone graft delivery, fixation products for treating thoracolumbar spine conditions, and anterior cervical plate systems for spinal fusion. Spine Wave prioritizes a surgeon-driven product development approach, enabling it to create a differentiated portfolio of less invasive and efficient surgical solutions aimed at restoring spinal function and improving patients' quality of life. The company's products are distributed through various channels, ensuring wide accessibility for spine surgeons and their patients.